PRS47 Assessing Quality Of Life In Atopic Dermatitis Pediatric Patients Across 12 Countries In The Asia Pacific Region  by Azmi, S. & Abdul Aziz, S.H.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A239 
 
 
42.3% reported having both NT and EM symptoms, 32.7% reported either 
symptom, and 25.0% reported neither symptom. Mean (±SD) age was 60.2 (±8.0) 
years and the majority of respondents were female (60.5%), white (91.6%), and 
former/current smokers (87.1%). Among respondents with NT symptoms, the 
most commonly reported symptom was coughing (72.9%), followed by wheezing 
(69.2%), and shortness of breath (61.4%). 77.7% of respondents with NT 
symptoms reported sleep disturbance and 59.1% felt anxious due to NT 
symptoms. Among respondents with EM symptoms, the most frequently 
reported symptom was coughing (74.5%), followed by shortness of breath (73.9%), 
and bringing up phlegm or mucus (69.6%). Of respondents with EM symptoms, 
60.4% reported morning activity limitation and 54.3% felt anxious due to EM 
symptoms. CONCLUSIONS: NT/EM symptoms are highly prevalent in the COPD 
population, especially cough and wheezing. The presence of these symptoms 
interferes with patients’ sleep, anxiety, and morning activities.  
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Talbert M1, McKown S2, Gawlicki MC3, Brandt BA3 
1Corporate Translations Inc., Chicago, IL, USA, 2Corporate Translations, Inc., Chicago, IL, USA, 
3Corporate Translations, Inc., East Hartford, CT, USA  
OBJECTIVES: To analyze subjects’ interpretation of concepts specific to Chronic 
Obstructive Pulmonary Disorder (COPD) during pilot testing of translated Patient 
Reported Outcomes (PRO) questionnaires. As observed during pilot testing of 
translated COPD questionnaires, COPD-specific concepts were observed to cause 
more comprehension difficulties across languages, compared to observed 
questionnaires for other diseases. Solutions for these comprehension difficulties 
in COPD questionnaires will be explored. METHODS: Pilot testing data for the 
concepts rescue medication, wheezing, the acronym COPD, and chest tightness 
within PROs were analyzed. Testing was conducted with five subjects per 
language for three questionnaires. Subjects were asked to paraphrase the COPD 
questionnaires in their entirety. Suggestions for improved comprehension of 
COPD concepts were explored, resulting from pilot testing data. RESULTS: 
Rescue medication caused difficulty within half of the languages analyzed. To 
improve comprehension, subjects suggested supplementing rescue medication 
with “(fast acting and quick relief medication)” for improved comprehension. 
Wheezing was a problematic concept for Spanish, South African Bantu and Indian 
languages. The subjects’ proposed solution for these languages was 
supplementation of wheezing with “(heavy breathing accompanied by a whistle 
sound).” Use of the COPD acronym proved problematic for 27% of languages. 
Even in languages where an equivalent acronym exists, comprehension issues 
persisted. Subjects suggested expansion of the acronym to “Chronic Obstructive 
Pulmonary Disorder.” Chest tightnesscaused minimal comprehension issues 
which were not significant enough to merit usable suggestions. CONCLUSIONS: 
Following translation of COPD questionnaires, pilot testing in the target language 
is essential, as concepts specific to COPD are found to be difficult.  
Because medical and technical concepts cannot be substituted, supplementation 
with brief definitions for increased comprehension and expansion of  
acronyms is recommended when developing source PRO questionnaires specific 
to COPD.  
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PATIENT-REPORTED QUALITY OF LIFE AND DYSPNEA AMONG COPD PATIENTS 
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OBJECTIVES: To assess quality of life (QoL) and dyspnea among chronic 
obstructive pulmonary disease (COPD) patients with/without nighttime (NT) 
and/or early morning (EM) symptoms. METHODS: This study was a cross-
sectional patient survey. Administrative claims from the HealthCore Integrated 
Research Database were utilized to identify commercially-insured patients, aged 
≥40 years, with ≥1 medical claim with an ICD-9-CM diagnosis code of COPD or ≥1 
pharmacy claim for COPD maintenance medication between September 1, 2010-
August 31, 2011. Consenting respondents completed a 25-minute survey that 
included screening questions classifying them as having NT/EM symptoms based 
on whether they experienced symptoms ≥3 nights/mornings in the past week. 
An attempt was made to maximize balance across groups with patients 
qualifying for closed groups being terminated. Patient-reported outcomes 
included the Short Form-12 version 2 (SF-12v2), the COPD Assessment Test 
(CAT), and the modified Medical Research Council (mMRC) dyspnea scale. 
Analysis of variance and chi-square were used to evaluate outcome differences 
among symptom groups. RESULTS: Of 752 respondents completing the survey, 
42.3% reported having both NT/EM symptoms, 32.7% reported either NT or EM 
symptoms, and 25.0% reported neither symptoms. Mean (±SD) age was 60.2 (±8.0) 
years and the majority of respondents were female (60.5%), white (91.6%), and 
former/current smokers (87.1%). Compared to respondents without symptoms, 
those with both or either NT/EM symptoms reported worse QoL and dyspnea as 
indicated by significantly lower SF-12v2 Physical Component Summary (PCS) and 
Mental Component Summary (MCS) mean scores (PCS: 34.0 vs 38.6 vs 43.8, 
p<0.01; MCS: 47.0 vs 52.8 vs 54.3, p<0.01), as well as higher CAT and mMRC mean 
scores (CAT: 21.6 vs 13.8 vs 9.1, p<0.01; mMRC: 1.8 vs 1.1 vs 0.8, p<0.01). 
CONCLUSIONS: COPD patients with NT/EM symptoms reported worse QoL and 
dyspnea scores compared with patients without symptoms. Improved 
management of NT/EM symptoms may decrease the burden associated with 
these symptoms.  
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OBJECTIVES: In the USA, chronic cough (CC) is the most common complaint for 
which patients seek medical attention (McGarvey, 2007). When assessing new 
treatments for CC in clinical trials, patient reported outcomes (PROs) are 
important methodologies for evaluating effectiveness. The objective of this 
literature review was to identify validated PRO instruments that can assess 
patients’ experience of (new) cough therapies in idiopathic chronic cough (ICC) 
and CC in chronic obstructive pulmonary disease (COPD), idiopathic pulmonary 
fibrosis (IPF) and lung cancer. METHODS: Literature search according to pre-
defined strategy and review criteria was performed in multiple databases. This 
search resulted in 33 included full-texts from which 9 relevant PROs were 
identified. RESULTS: The main questionnaires investigated in the included 
publications were the Leicester Cough Questionnaire (LCQ), the Chronic Cough 
Impact Questionnaire (CCIQ), and the Cough Visual Analogue Scale (VAS). Other 
cough specific PROs reviewed were the Cough Quality of Life Questionnaire 
(CQLQ), the Cough Symptom Diary (CSD) and the Adverse Cough Outcome 
Survey (ACOS). Some cough relevant items were included in the Breathlessness 
Cough and Sputum Scale (BCSS), the St. George’s Respiratory Questionnaire 
(SGRQ) and the Cough and Sputum Assessment Questionnaire (CASAQ). All 
instruments are relatively new and need further content validity, responsiveness 
and interpretability testing. Overall, the LCQ was the most psychometrically 
sound. The CSD has potential to be a high quality measure; it is the only PRO 
that provided a conceptual framework and measures cough severity; however, 
some major aspects still need to be validated. No questionnaire has been 
developed specifically for the population of interest; and few have been validated 
within this population. CONCLUSIONS: Several relevant instruments for ICC and 
CC trials exist, but they are relatively new and need further validation. The two 
most promising PROs are the LCQ for disease-specific quality-of-life and the CSD 
for cough severity.  
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A CROSS-SECTIONAL, HYBRID, PATIENT SURVEY AND CHART REVIEW STUDY 
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OBJECTIVES: To describe the design and execution of a hybrid, cross-sectional 
study of COPD patients, highlighting important strengths, weaknesses, and 
general considerations for use in burden of illness and health economic 
analyses. METHODS: A cross-sectional, observational study of 407 COPD patients 
was conducted in 3 centers in the southeastern region of the U.S. This hybrid 
study combined a cross-sectional patient survey and retrospective chart review. 
All patients diagnosed with COPD managed by a primary care physician (PCP) or 
pulmonologist who had their most recent visit within the eligibility period were 
invited to complete a baseline survey; chart data was abstracted by site medical 
staff for all patients who consented and completed the survey. Each clinic 
enrolled patients in 2 cohorts: COPD patients managed primarily by a PCP 
(N=152; male: 49.3 %; mean age: 70.9±9.5 years) veersus pulmonologist (N=255; 
male: 50.6%; mean age: 71.2±8.9 years). Anonymized patient data was recorded 
in a secure web-based database: demographics, clinical characteristics, COPD 
exacerbations and severity, resource utilization, treatment, symptoms, daily 
functioning, and quality of life. Key design challenges related primarily to patient 
recruitment: identifying a PCP versus pulmonologist for patient subgroup 
assignment; identification of COPD patients through comprehensive medical 
chart review; mitigation of selection bias for severe COPD cases that are more 
likely to visit an HCP for COPD-related reasons only; missing medical chart data; 
and temporality and causality associated with study outcomes. RESULTS: The 
key operational challenges were maximizing survey response rates and 
completeness of chart review with limited possibility of follow-up. 
CONCLUSIONS: Cross-sectional design is an efficient method of collecting data 
in COPD patients that could be used for health services research. However, it is 
associated with design and operational challenges that can be anticipated and 
mitigated early in study planning and conceptualization.  
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OBJECTIVES: Atopic dermatitis (AD) is a common chronic skin condition in 
childhood that has negative impact on both patients and their families. A survey 
was conducted to evaluate the disease burden, quality of life (QOL) and financial 
impact of moderate to severe pediatric AD in the Asia Pacific region. This 
analysis focuses on the QOL impact of pediatric AD. METHODS: A cross sectional 
online survey was conducted among 1028 parents of children with moderate to 
severe AD in 12 countries: Australia, China, Hong Kong, India, Indonesia, Korea, 
Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam. The Infant’s 
Dermatitis Quality of Life Index (IDQOL) was used for children less than 4 years 
old and the Children’s Dermatology Life Quality Index (CDLQI) for those aged 
between 4 to 16 years. The Dermatitis Family Impact (DFI) was used to assess the 
impact on family life. The maximum score for all three questionnaires is 30, 
categorized into 5 effect groups; none (0-1), small (2-6), moderate (7-12), very 
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large (13-18) and extremely large effects (19-30). Severity of disease was 
measured using the Nottingham Eczema Severity scores (NESS). RESULTS: The 
average QOL scores reported were 15.0±6.69 among infants (IDQOL); 16.4±7.25 
among children (CDLQI), and 15.5±7.59 among families (DFI). The mean IDQOL, 
CDLQI and DFI scores were higher in patients with severe AD (16.7±6.66, 
18.4±6.99, and 17.5±7.53, respectively) than among those with moderate AD 
(13.9±6.49, 15.2±7.14, and 14.2±7.35, respectively). A large proportion of 
respondents experienced extremely large effect of QOL scores (scoring 19 to 30), 
including 35.6% of infants, 44.0% of children and 39.1% of families. There were 
also large differences between the reported QOL from different countries. 
CONCLUSIONS: The study found that moderate to severe AD affected the QOL of 
the majority of patients and their families among respondents in the countries 
surveyed.  
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IMPACT OF SEVERE AND VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY 
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SURVEY AND CHART REVIEW OF RECENTLY EXACERBATING PATIENTS  
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BACKGROUND: Understanding COPD exacerbation-associated burden, 
particularly in severe (SEV) and very severe (VSEV) patients, can help improve 
medication management. OBJECTIVES: To describe exacerbation frequency, 
treatment, work productivity, and health-related quality of life (HRQoL) for 
patients with SEV/VSEV COPD who recently experienced a moderate (MOD)/SEV 
exacerbation. METHODS: A nationally representative sample of SEV/VSEV COPD 
patients who had experienced a MOD/SEV exacerbation within the past 3 
months was physician recruited. Medical charts were evaluated for patient 
demographic/clinical data, including exacerbation frequency in the previous 12 
months, work productivity and impairment (WPAI), and HRQoL (St. George’s 
Respiratory Questionnaire for COPD, SGRQ-C). RESULTS: This study included 314 
patients (190 SEV/124 VSEV). VSEV (vs. SEV) patients were more likely to be 
Caucasian (93.5% versus 82.1%, P=0.004) and had SEV last exacerbation (44.3% vs. 
29.5%, P=0.016). These 314 patients experienced 829 exacerbations in the 
previous 12 months, of which 556 were MOD (17.2% treated with antibiotics only; 
70.7% with steroids and antibiotics; 12.1% with steroids only), and 273 were SEV 
(19.6% treated in the ER; 53.7% hospitalized with an ER visit; 26.7% hospitalized 
without ER visit). 15.9% of patients (SEV 19.5%/VSEV 10.5%, P=0.033) were 
employed but reported a high percentage of overall work impairment 
(42.4%±31.1%) due to absenteeism/presenteeism. Activity impairment was 
58.7%±28.0% across all patients. SGRQ-C scores (0-100=best-worst health) were: 
Total 64.7±20.4, Symptoms 70.6±19.0, Activities 78.0±21.9, and Impacts 54.7±24.8, 
with total scores being significantly worse for VSEV (vs. SEV COPD; 70.1±21.3 vs. 
61.1±19.0; P<0.001) and SEV last exacerbation (vs. MOD; 70.3±19.9 vs. 61.7±20.1; 
P<0.001). CONCLUSIONS: MOD/SEV exacerbations in SEV/VSEV COPD patients 
impaired patients’ work productivity and were associated with poor HRQoL. 
Since patients with a recent MOD/SEV exacerbation were highly likely to have 
experienced mild/MOD/SEV exacerbations in the previous year, interventions to 
further reduce exacerbations will likely have a strong impact on patient HRQoL.  
 
RESPIRATORY-RELATED DISORDERS – Health Care Use & Policy Studies 
 
PRS49  
MULTICOMPONENT HOME-BASED ENVIRONMENTAL INTERVENTIONS ARE 
EFFECTIVE IN REDUCING MORBIDITY OF CHILDREN WITH ASTHMA FROM LOW 
INCOME FAMILIES  
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OBJECTIVES: To analyze the effectiveness of a multicomponent home-based 
environmental asthma intervention targeting children from low income families 
in East Harlem, New York City. METHODS: Three hundred eighty children aged 
17 years or younger with asthma participated in the study. These children and 
their families were assessed for baseline characteristics including asthma 
symptoms and health care utilization experienced by a child; presence of home 
environmental triggers; and parents’ knowledge and skills in managing the 
child’s asthma. Based on baseline characteristics, families that received 
environmental intervention (n=200) were compared with those that did not 
(n=18). The main asthma outcomes were rates of emergency department visits 
(edv), hospitalizations (hsp), asthma symptom days (asd), school days missed 
(sdm), and work days missed (wdm) due to asthma. Observable variables 
included age, gender, race, and baseline rates of edv, hsp, asd, sdm, and wdm. 
The effect of the intervention was measured as the difference in the main 
asthma outcomes at the baseline and at post-intervention assessment. To 
reduce the influence of confounding factors we applied propensity score method 
to estimate effect of the intervention on the main asthma outcomes. RESULTS: 
Baseline main asthma outcomes were: 2.56 (intervention group) and 2.64 (control 
group) for edv, 0.44 and 0.62 for hsp, 7.35 and 5.86 for asd, 5.38 and 6.96 for sdm, 
and 6.95 and 3.57 for wdm. The average treatment effect of the intervention was 
2.13 for edv, 0.92 for hsp, 2.67 for asd, 1.95 for sdm, and 1.89 for wdm. All 
estimates, except hospitalizations, were significant. The unmatched outcomes 
for the same outcomes were 3.36, -0.17, 3.80, 1.66, and 1.48 respectively. 
CONCLUSIONS: The results of the study suggest that low-income families can 
benefit from the intervention by reducing emergency department visits, asthma 
symptom days, and missed school and work days.  
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OBJECTIVES: The National Quality Forum (NQF) has endorsed measures from the 
Pharmacy Quality Alliance (PQA) for suboptimal asthma control (SAC) and 
absence of controller therapy (ACT) to measure the quality of care among 
asthma beneficiaries. The purpose of this study was to evaluate a baseline for 
the Mississippi Division of Medicaid using the PQA measures. METHODS: A 
retrospective cross-sectional analysis of 2008-2012 Mississippi Medicaid claims 
was undertaken. Asthma beneficiaries aged 5 - 50 years as of the last day of each 
measurement year were identified. The inclusion and exclusion criteria were 
applied according to the PQA measure specifications, with an expanded age 
inclusion to account for Medicaid’s pediatric population. Beneficiaries with at 
least 3 canisters of short-acting beta agonists within 90 days were identified as 
those with SAC. Of SAC beneficiaries, those who did not receive controller 
therapy including inhaled steroids, long-acting beta agonists, and leukotriene 
inhibitors in the same 90 day period were defined as those with ACT. Costs were 
compared between ACT and non-ACT beneficiaries for each measurement year. 
RESULTS: A total of 62,557 beneficiaries were identified from 2008 to 2012. The 
percentage of asthma beneficiaries having SAC along with ACT decreased from 
8.08% (2008) to 5.15% (2012). Beneficiaries with ACT (compared to non-ACT 
beneficiaries) had significantly higher asthma-related total costs [$1,516.98 vs. 
$593.66 (2008); $1,571.98 versus $648.78 (2009); $1,586.06 versus $664.36 (2010); 
$1,748.73 versus $722.36 (2011); $1,750.64 versus $709.63 (2012)]. Cost differences 
between the two groups for all the years was significant (p<0.01). CONCLUSIONS: 
This study of an expanded SAC/ACT measure in a Medicaid population found 
that the proportion of ACT beneficiaries has consistently decreased since 2008; 
providing a baseline measure for future interventions. Since beneficiaries with 
ACT have higher costs than non-ACT beneficiaries, further decline in the 
numbers for this population is needed in the coming years.  
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OBJECTIVES: Smoking is one of the major risk factors in chronic obstructive 
pulmonary disease (COPD) patients, with 90% of deaths from COPD being 
attributable to smoking. According to the Centers for Disease Control and 
Prevention (CDC), smoking cessation reduces the risk of developing COPD. Still, 
little is known about the use of smoking cessation agents and the factors that 
affect their use among patients. The purpose of the study is to identify the socio-
demographic factors that affect the use of these agents among COPD patients. 
METHODS: A retrospective study was done to identify smokers having COPD 
(ICD9:490-496) and those who use smoking cessation agents from 2006-2010 
using Medical Expenditure Panel Survey (MEPS) data. A multiple logistic 
regression model was built to identify significant socio- demographic predictors 
associated with the use of smoking cessation agents. RESULTS: Out of 2218 
smokers with COPD, 176 reported use of smoking cessation agents during the 5 
year period. Logistic regression showed African Americans were less likely to use 
smoking cessation agents than Caucasians (OR=0.379, 95% CI 0.208-0.688), 
patients having public insurance were more likely to report use of these agents 
than other insurances (OR=2.619, 95% CI 1.265-5.422), and patients with higher 
educational levels (OR=1.127, 95% CI 1.043-1.217) were more likely to use these 
agents. CONCLUSIONS: Results showed that a large number of patients 
continued to smoke even after the diagnosis of COPD whereas; only 176 patients 
(8%) used smoking cessation agents. Race, educational level, and insurance 
status were significant predictors of smoking cessation agents’ use. Further 
research needs to be done to evaluate reasons for minimal use of these agents in 
COPD patients. Results showed inconsistent use of these agents among different 
population groups; hence there is a requirement for need based smoking 
cessation programs.  
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OBJECTIVES: To compare baseline demographics of long-acting beta-agonist 
(LABA) step down in asthma patients taking fluticasone propionate-salmeterol 
via Diskus (FSC). METHODS: A retrospective observational study using pharmacy 
and medical claims data (Market Scan Commercial Database, January 1, 2006 to 
December 31, 2010). Subjects were included if they had : 1) ≥ 2 FSC prescription 
claims prior to the index (step-down) date; 2) ≥ 1 asthma claim [ICD-9-CM] codes 
493.xx); 3) 12-64 years of age; and 4) continuously eligible for 12 months pre and 
post index. Subjects were excluded if they had: 1) COPD diagnosis (ICD-9 codes 
491.xx, 492, xx, 496.xx), or 2) ≥ 1 prescription claim for anti-cholinergics or 3) 
receipt of higher dose FSC or another asthma controller other than FSC or ICS 
after the index. Step-down was defined as reduction in dose of FSC (lower dose 
FSC) or moving to ICS only without the LABA (ICS monotherapy). These two 
cohorts were matched 1:3 with subjects that remained on the starting FSC dose 
